New obesity drug combo shows promise in early trial

NCT ID NCT06771115

Completed Disease control Sponsor: Zomagen Biosciences Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called VTX3232, given alone or with the weight-loss drug semaglutide, in 176 adults with obesity. The main goal was to check safety and side effects over 12 weeks. Researchers also measured changes in inflammation levels. The trial is complete, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VTX3232 (an experimental drug) and semaglutide (a weight-loss drug)
What this could lead to: If successful, this could point toward a new treatment option for obesity that reduces inflammation and helps with weight loss.
What could go wrong: This is an early phase 2a trial focused on safety, not weight loss. The results may not lead to an approved treatment, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

840001

Largo, Florida, 33761, United States
840002

Austin, Texas, 78705, United States
840003

Lake Forest, California, 92630, United States
840005

Birmingham, Alabama, 35235, United States
840006

Dallas, Texas, 75230, United States
840010

Waco, Texas, 76710, United States
840011

Long Beach, California, 90815, United States
840012

Ocoee, Florida, 34761, United States
840013

San Antonio, Texas, 78229, United States
840014

Newton, Kansas, 67114, United States
840015

Marrero, Louisiana, 70072, United States
840016

Port Orange, Florida, 32127, United States
840017

Marrero, Louisiana, 70072, United States
840018

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.